People: Vexim SA (ALVXM.PA)

ALVXM.PA on Paris Stock Exchange

10.81EUR
28 Nov 2014
Price Change (% chg)

€-0.17 (-1.55%)
Prev Close
€10.98
Open
€10.81
Day's High
€11.00
Day's Low
€10.80
Volume
2,004
Avg. Vol
4,819
52-wk High
€12.10
52-wk Low
€9.40

Search Stocks

Summary

Name Age Since Current Position

Bruce de la Grange

2011 Chairman of the Board

Vincent Gardes

2011 Chief Executive Officer

Jerome Marzinski

2013 Deputy Chief Executive Officer

Denis Thoral

Chief Financial Officer

Yves-Alain Ratron

2012 Chief Technology Officer

Vincent Lefauconnier

2008 Director of Sales

Delphine Gricourt

2013 Director of Marketing and Investor Relations

Edouard Arrubarrena

Executive Director

Marie-Pierre Hontas

2012 Clinical Affairs Director

Antoine Pau

2012 Director

Philippe Pouletty

54 Director - Representative of Truffle Capital

Jonas Larsson

2008 Independent Director

Kieran Murphy

2007 Independent Director

Biographies

Name Description

Bruce de la Grange

Mr. Bruce de la Grange has been Chairman of the Board of Vexim SA since December 2, 2011. Prior to this, he held the functions of Chairman of the Board and Chief Executive Officer of the Company from December 16, 2008. He was previously in charge of development for Plus Orthopedics before it was sold to Smith & Nephew in 2007. He was also Director General at DePuy, for France, Spain and Belgium, and then at Zimmer, where he supervised the European operations. Mr. de la Grange currently also serves as Chief Executive Officer of Bio Novations GmbH. He was Director of the MBA Institute in Paris. He holds a Masters of Business Administration degree from The Wharton School of the University of Pennsylvania.

Vincent Gardes

Mr. Vincent Gardes has been Chief Executive Officer of Vexim SA since December 2, 2011. He holds a Bachelor of Arts in Business Administration from INSEEC and a postgraduate Certificate of Leadership Capability from Glasgow Caledonian University. He began his career in 1995 at Stryker Spine as Europe Products Manager. From 1996 to 1999, he was promoted to the position of Sales and Marketing Manager for knees and spine at the Spanish subsidiary, Stryker Spain. Returning to France in 1999, he successively held the titles of Team Leader Hips for Stryker Europe and then Global Product Manager for Stryker Spine until 2002. At the end of 2002, Mr. Gardes joined the Medtronic Group where he held the position of Spine Europe Division Director. In 2004, he was promoted to Business Unit Manager Spine and Biologics, France, and then in 2007 to Southern Europe Business Director. From September 2008, Mr. Gardes was General Manager of CR Bard for Spain and Portugal based in Barcelona. From July 2011, he worked as a consultant for Truffle Capital with Vexim SA.

Jerome Marzinski

Mr. Jerome Marzinski has served as Deputy Chief Executive Officer of Vexim SA since October 2013, when he joined the Company. Mr. Marzinski began his professional career as a financial analyst at SGI, where he worked from 1995 to 1997. Next, he was Finance Manager at Hertz between 1998 and 1999. He subsequently joined Sun Microsystems Inc, where he held various management posts from 2000 to 2007. In 2007, he joined ev3 as International Financial Director and continued as Europe Chief Financial Director, the function he held from 2009 to 2012. Mr. Marzinski obtained a Masters degree in Finance from Universite Catholique de Lille in 1994 and also received a Masters of Business Administration degree from HEC in Paris in 2012.

Denis Thoral

Mr. Denis Thoral is Chief Financial Officer of Vexim SA, working for the Company as part of a consultant contract. He holds a Masters of Business Administration degree in Finance and Information Systems from Carnegie Mellon University (Tepper School). He started his career at Coopers & Lybrand and then joined Atari as a financial controller and IDS as Chief Financial Officer. He then founded his consulting company, ADGEST.

Yves-Alain Ratron

Mr. Yves-Alain Ratron has served as Chief Technology Officer of Vexim SA since September 6, 2012. Over the last 30 years, he has gained experience in the global orthopedic industry building and managing the Global Research & Development Department for the Tornier SA Group that he joined in 1982. During his tenure, he had several positions in Ireland, Grenoble, Canada in both Research & Development and Production functions. His last assignment from 2007 was Director of Global Research. He began his career at RALT Cars Ltd - Weybridge the United Kingdom. He holds a Bachelors degree in Mechanical Engineering from Ecole Nationale d'Ingenieurs de Tarbes (Ecole Nationale dIngenieurs de Tarbes).

Vincent Lefauconnier

Mr. Vincent Lefauconnier has been Director of Sales of Vexim SA since 2008. He has 12 years experience in marketing and sales in the spine field. He started his career in sales for Medtronic Surgical Navigation Technology before being named product manager in charge of new technologies for Medtronic Spine France. After a few years, he joined Stryker EMEA where he organized the launch of new products and technologies in the spinal, fracture, and orthobiology fields. He also worked on two projects for treating vertebral fractures.

Delphine Gricourt

Ms. Delphine Gricourt has been Director of Marketing and Investor Relations at Vexim SA since January 17, 2013. Ms. Gricourt started her career in the agri-food industry as Junior Product Manager at Danone in 1992, and moved up to a Product Manager and Group Head position at Saint Mamet. In 1999, she turned to event marketing and worked for the Lucien Barriere Group. From 2003 to 2010, she was Marketing Communications Manager first at Novartis and then at Fresenius laboratories where she developed strategic plans for the medical nutrition product line (class 2 medical device) aimed at hospitals and general practitioners. Following a mission as Project Manager for Marketing and Communication Strategic Review at Valade in 2010, she entered the medical device sector at Paul Boye Technologies. There, she held the position of Sales & Marketing Director in the Health Department and developed strategic plans for many products including class 1 medical device (orthotics and respiratory equipment).

Edouard Arrubarrena

Mr. Edouard Arrubarrena is Executive Director of Vexim SA. He holds a degree in Engineering, both from Ecole Nationale Superieure d’Arts et Metiers and Ecole Superieure d’Electricite. He was previously Senior Vice President of Thales before joining Vexim SA.

Marie-Pierre Hontas

Ms. Marie-Pierre Hontas has been Clinical Affairs Director at Vexim SA since May 2012. She has 20 years' experience in international clinical research, acquired in the pharmaceutical and medical device industries.

Antoine Pau

Mr. Antoine Pau has been Director of Vexim SA since March 19, 2012. He is a Pharmacist and graduated from ESSEC Business School. He started his career ay Novartis Pharma working in the Business Planning Analysis department of the Oncology Business Unit. He then worked for three years at Mazars as a Financial Auditor, and was in charge of the legal audit of pharmaceutical and biotechnology companies and investment funds. At Mazars, he also took part in financial due diligence of technology companies within the transaction services department. He joined Truffle Capital in 2008 and currently serves as Director of Investments in Life Sciences. He is also a Lecturer at Science Po Paris.

Philippe Pouletty

Dr. Philippe Pouletty is Director - Representative of Truffle Capital at Vexim SA. A Doctor of Medicine, Immunologist, former intern of the Paris Hospitals, laureate from Pasteur Institute (immunology) and postdoctoral fellow at Stanford University, he is the inventor of 29 patents. Dr. Pouletty is the Founder and Managing Director of Truffle Capital and was the President of France Biotech, the French association of biotechnology companies, and former Vice President of EuropaBio, the European Federation of Biotechnology. He was also the founder of three biotechnology companies in Europe and the United States and is a member of the board of several biotechnology and medical device companies in Europe and North America, including BMD, Carmat, Deinove, Innate Pharma, ITS, Neovacs, Pharnext, PlasmaPrime, Splicos, Symetis, Theraclion and Wittycell. Dr. Pouletty also took part in several governmental initiatives in France, including the 1999 act to for simplifying company law (SAS), the Plan Biotech 2002 for launching and developing biotechnology and the Young Innovative Enterprise status which have tax exemptions to technology companies. He obtained a Doctorate of Medicine degree from Universite Paris VI Pierre et Marie Curie. He also received a degree in Immunology from Institut Pasteur, Paris and graduated from the Stanford University.

Jonas Larsson

Mr. Jonas Larsson has been Independent Director of Vexim SA since December 16, 2008. For the past 16 years, he has occupied several positions in general management, mainly in the medical instruments industry. In 2000, Mr. Larsson joined Stryker and served as Managing Director of the Stryker Nordic subsidiary and Vice President of Marketing at Stryker EMEA. Since 2006, he has been the Vice President and General Manager of IDEXX for Europe, Middle East and Africa. He also serves as a Director of Picovitro AB, Diavet Labor AG, IDEXX Europe B.V., IDEXX Laboratories B.V., IDEXX Laboratories Oy and IDEXX Switzerland AG.

Kieran Murphy

Mr. Kieran Murphy has been Independent Director of Vexim SA since November 30, 2007. He is a medical doctor and associate of the Royal College of Physicians and Surgeons of Canada. He is the Vice President and Manager of the Medical Imaging Department of the University of Toronto and Director of International Medical Strategy for University Health Network (UHN). From 1998 to 2008, Mr. Murphy was the Director of the Interventional Radiology Department of John Hopkins Hospital in Baltimore. He is also a Director of Active O Inc and Cognitive Vision Inc.
Search Stocks